INXN 2001

Drug Profile

INXN 2001

Alternative Names: Ad-IL-12; Ad-RTS-hIL-12; Ad-RTS-IL-12; Ad-RTS-mIL-12; ZIN-ATI-001

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator ZIOPHARM Oncology
  • Class Antineoplastics; Cell therapies; Gene therapies; Small molecules
  • Mechanism of Action Gene transference; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Glioma
  • Suspended Malignant melanoma
  • Discontinued Colorectal cancer

Most Recent Events

  • 17 Nov 2016 Efficacy data from a phase I trial and pharmacodynamics data from preclinical studies in Glioma released by ZIOPHARM Oncology
  • 09 Nov 2016 ZIOPHARM plans a phase I trial in Brain cancer (In children)
  • 10 Oct 2016 Interim efficacy, drug interaction and adverse event data from a phase I/II trial in Breast cancer (Late-stage disease) in USA (Intratumoural) presented at the 41st European Society for Medical Oncology (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top